Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade

References

• Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50(12):1–17. doi:10.1038/s12276-018-0191-1.
   PubMed Web of Science ®Google Scholar
• Yi M, Niu M, Xu L, Luo S, Wu K. Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol. 2021;14(1):10. doi:10.1186/s13045-020-01027-5.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–330. doi:10.1038/nature21349.
   PubMed Web of Science ®Google Scholar
• Abe BT, Macian F. Uncovering the mechanisms that regulate tumor-induced T-cell anergy. Oncoimmunology. 2013;2(2):e22679. doi:10.4161/onci.22679.
   PubMed Web of Science ®Google Scholar
• Chester C, Sanmamed MF, Wang J, Melero I. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood. 2018;131(1):49–57. doi:10.1182/blood-2017-06-741041.
   PubMed Web of Science ®Google Scholar
• Vinay DS, Kwon BS. Immunotherapy of cancer with 4-1BB. Mol Cancer Ther. 2012;11(5):1062–1070. doi:10.1158/1535-7163.Mct-11-0677.
   PubMed Web of Science ®Google Scholar
• Bremer E. Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy. ISRN Oncol. 2013;2013:371854. doi:10.1155/2013/371854.
   PubMedGoogle Scholar
• Choi BK, Lee SC, Lee MJ, Kim YH, Kim YW, Ryu KW, Lee JH, Shin SM, Lee SH, Suzuki S, et al. 4-1BB-based isolation and expansion of CD8+ T cells specific for self-tumor and non-self-tumor antigens for adoptive T-cell therapy. J Immunother. 2014;37(4):225–236. doi:10.1097/cji.0000000000000027.
   PubMed Web of Science ®Google Scholar
• Wolfl M, Kuball J, Ho WY, Nguyen H, Manley TJ, Bleakley M, Greenberg PD. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood. 2007;110(1):201–210. doi:10.1182/blood-2006-11-056168.
   PubMed Web of Science ®Google Scholar
• Wilcox RA, Tamada K, Flies DB, Zhu G, Chapoval AI, Blazar BR, Kast WM, Chen L. Ligation of CD137 receptor prevents and reverses established energy of CD8+ cytolytic T lymphocytes in vivo. Blood. 2004;103(1):177–184. doi:10.1182/blood-2003-06-2184.
   PubMed Web of Science ®Google Scholar
• Weigelin B, Bolaños E, Teijeira A, Martinez-Forero I, Labiano S, Azpilikueta A, Morales-Kastresana A, Quetglas JI, Wagena E, Sánchez-Paulete AR, et al. Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb. Proc Natl Acad Sci U S A. 2015;112(24):7551–7556. doi:10.1073/pnas.1506357112.
   PubMed Web of Science ®Google Scholar
• Williams JB, Horton BL, Zheng Y, Duan Y, Powell JD, Gajewski TF. The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment. J Exp Med. 2017;214(2):381–400. doi:10.1084/jem.20160485.
   PubMed Web of Science ®Google Scholar
• Chen S, Lee L-F, Fisher TS, Jessen B, Elliott M, Evering W, Logronio K, Tu GH, Tsaparikos K, Li X, et al. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model. Cancer Immunol Res. 2015;3(2):149–160. doi:10.1158/2326-6066.Cir-14-0118.
   PubMed Web of Science ®Google Scholar
• Dai M, Yip YY, Hellstrom I, Hellstrom KE. Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies. Clin Cancer Res. 2015;21(5):1127–1138. doi:10.1158/1078-0432.Ccr-14-1339.
   PubMed Web of Science ®Google Scholar
• Wei H, Zhao L, Hellstrom I, Hellstrom KE, Guo Y. Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy. Oncoimmunology. 2014;3(4):e28248. doi:10.4161/onci.28248.
   PubMed Web of Science ®Google Scholar
• Segal NH, Logan TF, Hodi FS, McDermott D, Melero I, Hamid O, Schmidt H, Robert C, Chiarion-Sileni V, Ascierto PA, et al. Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody. Clin Cancer Res. 2017;23(8):1929–1936. doi:10.1158/1078-0432.Ccr-16-1272.
   PubMed Web of Science ®Google Scholar
• Segal NH, He AR, Doi T, Levy R, Bhatia S, Pishvaian MJ, Cesari R, Chen Y, Davis CB, Huang B, et al. Phase I study of single-agent utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in patients with advanced cancer. Clin Cancer Res. 2018;24(8):1816–1823. doi:10.1158/1078-0432.CCR-17-1922.
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Sznol M, Hu-Lieskovan S, Papadopoulos KP, Patnaik A, Rasco DW, Di Gravio D, Huang B, Gambhire D, Chen Y, et al. Phase Ib study of utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in combination with pembrolizumab (MK-3475) in patients with advanced solid tumors. Clin Cancer Res. 2017;23(18):5349–5357. doi:10.1158/1078-0432.Ccr-17-1243.
   PubMed Web of Science ®Google Scholar
• Chin SM, Kimberlin CR, Roe-Zurz Z, Zhang P, Xu A, Liao-Chan S, Sen D, Nager AR, Oakdale NS, Brown C, et al. Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab. Nat Commun. 2018;9(1):4679. doi:10.1038/s41467-018-07136-7.
   PubMed Web of Science ®Google Scholar
• Vanamee ÉS, Faustman DL. Structural principles of tumor necrosis factor superfamily signaling. Sci Signal. 2018;11(511):511. doi:10.1126/scisignal.aao4910.
   Web of Science ®Google Scholar
• Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the ‘high-hanging fruit’. Nat Rev Drug Discov. 2018;17(3):197–223. doi:10.1038/nrd.2017.227.
   PubMed Web of Science ®Google Scholar
• Rabu C, Quéméner A, Jacques Y, Echasserieau K, Vusio P, Lang F. Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity. J Biol Chem. 2005;280(50):41472–41481. doi:10.1074/jbc.M506881200.
   PubMed Web of Science ®Google Scholar
• Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, Wilson NS, Dranoff G, and Brogdon JL. Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med. 2013;210(9):1685–1693. doi:10.1084/jem.20130573.
   PubMed Web of Science ®Google Scholar
• Fellermeier S, Beha N, Meyer JE, Ring S, Bader S, Kontermann RE, Müller D. Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format. Oncoimmunology. 2016;5(11):e1238540. doi:10.1080/2162402x.2016.1238540.
   PubMed Web of Science ®Google Scholar
• Bartkowiak T, Jaiswal AR, Ager CR, Chin R, Chen CH, Budhani P, Ai M, Reilley MJ, Sebastian MM, Hong DS, et al. Activation of 4-1BB on liver myeloid cells triggers hepatitis via an interleukin-27-dependent pathway. Clin Cancer Res. 2018;24(5):1138–1151. doi:10.1158/1078-0432.Ccr-17-1847.
   PubMed Web of Science ®Google Scholar
• Qi X, Li F, Wu Y, Cheng C, Han P, Wang J, Yang X. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity. Nat Commun. 2019;10(1):2141. doi:10.1038/s41467-019-10088-1.
   PubMed Web of Science ®Google Scholar
• Claus C, Ferrara C, Xu W, Sam J, Lang S, Uhlenbrock F, Albrecht R, Herter S, Schlenker R, Hüsser T, et al. Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. Sci Transl Med. 2019;11(496):496. doi:10.1126/scitranslmed.aav5989.
   Web of Science ®Google Scholar
• Junttila TT, Li J, Johnston J, Hristopoulos M, Clark R, Ellerman D, Wang B-E, Li Y, Mathieu M, Li G, et al. Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells. Cancer Res. 2014;74(19):5561–5571. doi:10.1158/0008-5472.Can-13-3622-t.
   PubMed Web of Science ®Google Scholar
• Hinner MJ, Aiba RSB, Jaquin TJ, Berger S, Dürr MC, Schlosser C, Allersdorfer A, Wiedenmann A, Matschiner G, Schüler J, et al. Tumor-localized costimulatory T-cell engagement by the 4-1BB/HER2 bispecific antibody-anticalin fusion PRS-343. Clin Cancer Res. 2019;25(19):5878–5889. doi:10.1158/1078-0432.Ccr-18-3654.
   PubMed Web of Science ®Google Scholar
• Compte M, Harwood SL, Muñoz IG, Navarro R, Zonca M, Perez-Chacon G, Erce-Llamazares A, Merino N, Tapia-Galisteo A, Cuesta AM, et al. A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity. Nat Commun. 2018;9(1):4809. doi:10.1038/s41467-018-07195-w.
   PubMed Web of Science ®Google Scholar
• Piha-Paul S, Bendell J, Tolcher A, Hurvitz S, Patnaik A, Shroff R, Pohlmann P, Zettl M, Hahn N, Krishnamurthy A, et al. Phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies. J Immunother Cancer.2020;8(Suppl 1) doi:10.1136/LBA2019.2.
   Google Scholar
• Slaga D, Ellerman D, Lombana TN, Vij R, Li J, Hristopoulos M, Clark R, Johnston J, Shelton A, Mai E, et al. Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3. Sci Transl Med. 2018;10:463. doi:10.1126/scitranslmed.aat5775.
   Web of Science ®Google Scholar
• Klein C, Sustmann C, Thomas M, Stubenrauch K, Croasdale R, Schanzer J, Brinkmann U, Kettenberger H, Regula JT, and Schaefer W. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs. 2012;4(6):653–663. doi:10.4161/mabs.21379.
   PubMed Web of Science ®Google Scholar
• Pacchiana G, Chiriaco C, Stella MC, Petronzelli F, De Santis R, Galluzzo M, Carminati P, Comoglio PM, Michieli P, Vigna E, et al. Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. J Biol Chem. 2010;285(46):36149–36157. doi:10.1074/jbc.M110.134031.
   PubMed Web of Science ®Google Scholar
• Mazor Y, Oganesyan V, Yang C, Hansen A, Wang J, Liu H, Sachsenmeier K, Carlson M, Gadre DV, Borrok MJ, et al. Improving target cell specificity using a novel monovalent bispecific IgG design. MAbs. 2015;7(2):377–389. doi:10.1080/19420862.2015.1007816.
   PubMed Web of Science ®Google Scholar
• Mazor Y, Hansen A, Yang C, Chowdhury PS, Wang J, Stephens G, Wu H, Dall’Acqua WF. Insights into the molecular basis of a bispecific antibody’s target selectivity. MAbs. 2015;7(3):461–469. doi:10.1080/19420862.2015.1022695.
   PubMed Web of Science ®Google Scholar
• Egan TJ, Diem D, Weldon R, Neumann T, Meyer S, Urech DM. Novel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments. MAbs. 2017;9(1):68–84. doi:10.1080/19420862.2016.1248012.
   PubMed Web of Science ®Google Scholar
• Novarra S, Grinberg L, Rickert KW, Barnes A, Wilson S, Baca M. A hingeless Fc fusion system for site-specific cleavage by IdeS. MAbs. 2016;8(6):1118–1125. doi:10.1080/19420862.2016.1186321.
   PubMed Web of Science ®Google Scholar
• Kabsch W. XDS. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt2):125–132. doi:10.1107/s0907444909047337.
   PubMedGoogle Scholar
• McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr. 2007;40(Pt 4):658–674. doi:10.1107/s0021889807021206.
   PubMed Web of Science ®Google Scholar
• Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr. 1997;53(Pt 3):240–255. doi:10.1107/s0907444996012255.
   PubMedGoogle Scholar
• Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 4):486–501. doi:10.1107/s0907444910007493.
   PubMed Web of Science ®Google Scholar
• Eskiocak U, Guzman W, Wolf B, Cummings C, Milling L, Hj W, Ophir M, Lambden C, Bakhru P, Gilmore DC, et al. Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity. JCI Insight. 2020;5:5. doi:10.1172/jci.insight.133647.
   Web of Science ®Google Scholar
• Tan S, Liu K, Chai Y, Zhang CW, Gao S, Gao GF, Qi J. Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab. Protein Cell. 2018;9(1):135–139. doi:10.1007/s13238-017-0412-8.
   PubMed Web of Science ®Google Scholar
• Wyzgol A, Müller N, Fick A, Munkel S, Grigoleit GU, Pfizenmaier K, Wajant H. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J Immunol. 2009;183(3):1851–1861. doi:10.4049/jimmunol.0802597.
   PubMed Web of Science ®Google Scholar
• Coloma MJ, Morrison SL. Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol. 1997;15(2):159–163. doi:10.1038/nbt0297-159.
   PubMed Web of Science ®Google Scholar
• Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27(1):111–122. doi:10.1016/j.immuni.2007.05.016.
   PubMed Web of Science ®Google Scholar
• Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3–potential mechanisms of action. Nat Rev Immunol. 2015;15(1):45–56. doi:10.1038/nri3790.
   PubMed Web of Science ®Google Scholar
• Mayoux M, Roller A, Pulko V, Sammicheli S, Chen S, Sum E, Jost C, Fransen MF, Buser RB, Kowanetz M, et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci Transl Med. 2020;12(534):534. doi:10.1126/scitranslmed.aav7431.
   Web of Science ®Google Scholar
• Oh SA, Wu D-C, Cheung J, Navarro A, Xiong H, Cubas R, Totpal K, Chiu H, Wu Y, Comps-Agrar L, et al. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nature Cancer. 2020;1(7):681–691. doi:10.1038/s43018-020-0075-x.
   PubMedGoogle Scholar
• Peng Q, Qiu X, Zhang Z, Zhang S, Zhang Y, Liang Y, Guo J, Peng H, Chen M, Fu Y-X, et al. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat Commun. 2020;11(1):4835. doi:10.1038/s41467-020-18570-x.
   PubMed Web of Science ®Google Scholar
• Heery CR, O’Sullivan-Coyne G, Madan RA, Cordes L, Rajan A, Rauckhorst M, Lamping E, Oyelakin I, Marté JL, Lepone LM, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 2017;18(5):587–598. doi:10.1016/s1470-2045(17)30239-5.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–567. doi:10.1038/nature14011.
   PubMed Web of Science ®Google Scholar
• Lakins MA, Koers A, Giambalvo R, Munoz-Olaya J, Hughes R, Goodman E, Marshall S, Wollerton F, Batey S, Gliddon D, et al. FS222, a CD137/PD-L1 tetravalent bispecific antibody, exhibits low toxicity and antitumor activity in colorectal cancer models. Clin Cancer Res. 2020;26(15):4154–4167. doi:10.1158/1078-0432.Ccr-19-2958.
   PubMed Web of Science ®Google Scholar
• Garralda E, Geva R, Ben-Ami E, Maurice-Dror C, Calvo E, LoRusso P, Türeci Ö, Niewood M, Şahin U, Jure-Kunkel M, et al. First-in-human phase I/IIA trial to evaluate the safety and initial clinical activity of duobody®-PD-L1×4–1BB (GEN1046) in patients with advanced solid tumors. J Immunother Cancer. 2020;8(Suppl 3):A437–A437. SITC Abstract 412. doi:10.1136/jitc-2020-SITC2020.0412.
   Web of Science ®Google Scholar
• Bol K, Marissen J, Elassiass-Schaap J, Tacken P, Engels S, Wang L-C, Mondal A, Throsby M, Roberts A, Mayes P, et al. MCLA −145 (CD137xPD 145 (CD137xPD -L1): a potent CD137 agonist and immune checkpoint inhibitor that does not show signs of peripheral toxicity in preclinical models. J Immunother Cancer. 2020. SITC 2020 Poster P814. doi:10.1136/jitc-2020-SITC2020.0814.
   Web of Science ®Google Scholar
• Zhai T, Wang C, Xu Y, Huang W, Yuan Z, Wang T, Dai S, Peng S, Pang T, Jiang W, et al. Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer. J Immunother Cancer. 2021;9(6):6. doi:10.1136/jitc-2020-002131.
   Web of Science ®Google Scholar
• Jeong S, Park E, Kim HD, Sung E, Kim H, Jeon J, Kim Y, Jung U-J, Son Y-G, Hong Y. Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade. J Immunother Cancer. 2021;9:7. doi:10.1136/jitc-2021-002428.
   Web of Science ®Google Scholar
• Garralda E, Geva R, Ben-Ami E, Maurice-Dror C, Calvo E, LoRusso P, Tureci O, Niewood M, Sahin U, Jure-Kinkel M, et al. First-in-human phase I/IIA trial to evaluate the safety and initial clinical activity of duobody-PD-L1x4-1BB (GEN1046) in patients with advanced solid tumors. J Immunother Cancer. 2020;8(Suppl 3):Abstract 412. doi:10.1136/jitc-2020-SITC2020.0412.
   Web of Science ®Google Scholar
• Bol K, Marissen W, Elassiass-Schaap J, Tacken P, Engels S, Wang L-C, Mondal A, Throsby M, Roberts A, Mayes P, et al. MCLA-145 (CD137xPD-L1): a potent CD137 agonist and immune checkpoint inhibitor that that does not show signs of peripheral toxicity. J Immunother Cancer. 2020;8(Suppl 3):Abstract 814. doi:10.1136/jitc-2020-SITC2020.0814.
   Web of Science ®Google Scholar